BTMD at a glance
biote Corp. (BTMD, SEC CIK 1819253) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), biote Corp. (BTMD) reported revenue of $192.2 million (down 2.5% from FY2024) and net income of $27.0 million. Diluted EPS was $0.74.
- The most recent insider open-market purchase reported on Form 4 was by Beer Marc D on August 11, 2026 of 16,000 shares at $1.55 per share.
- In the last 90 days, BTMD insiders reported 2 open-market purchases ($202K) and 0 open-market sales ($0) on Form 4, a net purchase of $202K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $192.2M
- −2.5% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$202K
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: hormone optimization training and Biote-branded dietary supplements sold to Biote-certified practitioners and partnered clinics
- Strategic emphasis on managing risks related to outsourcing facilities that compound bioidentical hormones, including recent acquisition of Asteria Health (Mar 2024)
- Geographic revenue concentration with 53% from TX, OK, NM, CO, AR, LA, MS, AL, GA, FL in FY 2025, highlighting regional regulatory sensitivity
- Key operational risk: termination notice from AnazaoHealth for Pharmacy Services Agreement, extended through Dec 2027 per 2025 amendment
- Growth-focused strategy may depress near-term profitability due to increased marketing, acquisitions and infrastructure scaling demands
Risk Factors
- Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm
- Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes
- Operational risk relating to vertical integration of Asteria Health, impacting cost structure with a 19.0% decrease in pellet procedure costs
- Market disruption from Amazon e-commerce channel growth boosting Biote-branded supplement revenue by $6.9M in 2025 as competitor distribution shifts
- Legal/financial risk from $4.9M legal settlement expense in 2024 (Carie Boyd case), reduction improved 2025 SG&A expense by 5.2% to $101.8M
AI summary of the BTMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Credit risk: amended Credit Agreement dated May 8, 2026, with Truist Bank as administrative agent
- Capital allocation risk: $4.8 million spent repurchasing 2,436,177 shares during the quarter
- Liquidity risk: approximately $5.2 million remaining under the share repurchase authorization
- Management continuity risk: Robert C. Peterson serving simultaneously as interim CEO, CFO, and chief business officer
AI summary of the BTMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, reported August 5, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue fell 9.5% to $44.2M, with procedure revenue down 13.9% to $30.3M from the January 2026 voluntary recall
- Gross margin contracted to 65.4% from 71.6% due to higher replacement-product costs and reduced Asteria Health manufacturing efficiency
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Interim CEO Robert Peterson receives $658,800 base salary and incentive eligibility up to 72.5% of salary
- Stock option award equals 0.56% of outstanding shares, with an additional equal award if appointed permanent CEO
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Exhibit 99.1 contains the company’s press release on the officer/director change
- Furnished, not filed, limiting Section 18 Exchange Act liability
Item 7.01: Regulation FD Disclosure
- May 28, 2026 press release disclosed management changes at biote Corp
- Management transition may affect execution, strategic continuity, and investor confidence
AI summaries of BTMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BTMD
Don't miss the next BTMD filing
- Alerts as it files. A push when BTMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BTMD, by share count.
- Ask anything. An AI agent that reads every BTMD filing and answers with sources.
BTMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Beer Marc D | Buy | Aug 11, 2026 | 16,000 | $1.55 |
| Beer Marc D | Buy | Aug 10, 2026 | 115,950 | $1.53 |
| Peterson Robert Charles | A | Jun 12, 2026 | 206,746 | - |
| Christensen Bret | A | Jun 8, 2026 | 130,000 | - |
| Beer Marc D | A | Jun 8, 2026 | 114,157 | - |
| Jacoby Dana Lynn | A | May 12, 2026 | 130,000 | - |
| HEYER ANDREW R | A | May 12, 2026 | 35,259 | - |
| HEYER ANDREW R | A | May 12, 2026 | 130,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $185.4M | $197.2M | $192.2M |
| Operating Income | - | $31.6M | $35.6M |
| Net Income | - | $3.2M | $27.0M |
| Op. Margin | - | 16.0% | 18.5% |
| Net Margin | - | 1.6% | 14.1% |
| Balance Sheet | |||
| Total Assets | - | $122.4M | $107.6M |
| Equity | -$29.4M | -$105.9M | -$58.5M |
| ROE | - | -3.0% | -46.2% |
| Per Share | |||
| EPS | $0.13 | $0.09 | $0.74 |
| Cash Flow | |||
| Operating CF | $26.9M | $45.2M | $35.2M |
| CapEx | - | $6.4M | $5.0M |
Source: XBRL data in biote Corp. (BTMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
BTMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 28, 2026 | - | - | |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Apr 3, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 10-K | Mar 13, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 8-K | Jan 26, 2026 | - | - | |
| 10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- DFTX · Definium Therapeutics, Inc.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- MDWD · MediWound Ltd.Medicinal Chemicals & Botanical Products
- NAGE · Niagen Bioscience, Inc.Medicinal Chemicals & Botanical Products
- USNA · USANA HEALTH SCIENCES INCMedicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
BTMD SEC filings: frequently asked questions
Are BTMD insiders buying or selling?
In the last 90 days, biote Corp. (BTMD) officers, directors and 10% owners reported 2 open-market purchases worth $202,204 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was BTMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), biote Corp. (BTMD) reported revenue of $192.2 million (down 2.5% from FY2024) and net income of $27.0 million. Diluted EPS was $0.74. The figures come from the XBRL data in the 10-K.
What are the main risks in BTMD's latest 10-K?
In the 10-K filed March 13, 2026, biote Corp. (BTMD) flagged: Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm. Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes. (AI summary of the Risk Factors section.)
What did BTMD report in its latest 8-K?
biote Corp. (BTMD) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026, reported August 5, 2026.
What are the latest BTMD SEC filings?
biote Corp. (BTMD) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on August 12, 2026.
What is BTMD's SEC CIK number?
biote Corp. (BTMD)'s SEC Central Index Key (CIK) is 1819253. EDGAR lists every BTMD filing under that number.
Ask anything about BTMD
The research agent reads BTMD's filings, financials, insider trades and 13F holders, then answers with sources.